Skip to header Skip to content Skip to footer

YPOG advises lead investor Vesalius Biocapital on Series C financing round of HepaRegeniX

Reading time: 1 minute

Berlin, July 2024 – YPOG advised the lead investor Vesalius Biocapital IV on the Series C financing round of HepaRegeniX GmbH. Existing investors such as Novo Holdings, Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds also participated in the investment.

HepaRegeniX GmbH is a clinical stage company developing novel therapies for the treatment of acute and chronic liver diseases. Since its launch in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). This substance has the potential to significantly support liver regeneration in patients with liver metastases or primary liver tumors.

The new funding will support the Phases Ib/ IIa clinical trial focused on improving liver healing and preventing liver failure.

Team

Dr. Martin Schaper (Lead, Transactions), Partner, Berlin
Dr. Lutz Schreiber (IP/IT/Data Protection), Partner, Hamburg
Benjamin Müller (Transactions), Associate, Berlin
Matthias Treude (IP/IT/Data Protection), Associate, Hamburg
Cyra Dittberner (Transactions), Associate, Berlin

About Vesalius Biocapital IV

Vesalius Biocapital is an established European life sciences venture capital investor with a long track record of consistent returns, investing in best/first-in-class European Biopharma and HealthTech companies.

The company is investing in appealing, later-stage companies in drug development, medical devices & diagnostics and eHealth / mHealth, predominantly in Europe. Its portfolio companies address unmet medical & market needs and operate on the basis of strong intellectual property protection.

 

Download Press Release: YPOG advises lead investor Vesalius Biocapital on Series C financing round of HepaRegeniX

About us

YPOG stands for You + Partners of Gamechangers. As a leading law and tax firm, YPOG supports founders, investors, companies and funds in Germany and internationally in bringing visionary ideas to life in the tech ecosystem and dynamic future markets.
YPOG advises on the structuring of venture capital and private equity funds, financing rounds and complex transactions, as well as on regulatory and tax matters relating to digital assets and financial innovation. As a strategic partner, YPOG develops practical solutions of the highest legal standard. 
The firm combines legal and tax expertise with legal tech, digital workflows and AI-based systems to provide efficient and scalable advice.
YPOG and its professionals are regularly recognised by JUVE, Chambers and Partners, The Legal 500, Best Lawyers and Leaders League. More than 380 lawyers, tax advisers, tax specialists, one notary and business professionals work for YPOG across its offices in Berlin, Cologne, Hamburg and Munich. 

Further information: www.ypog.law/en/ and www.linkedin.com/company/ypog

More articles

Explore all